Advancing Life-Changing Medicines as President of Project Farma (PF) and Precision for Medicine Manufacturing Solutions
The surge in approvals for #cellandgenetherapy (CGT) products offers hope for patients with chronic and #rarediseases that have long been without treatment options. The robust pipeline of innovative treatments presents compelling opportunities for investors, not only in early-stage ventures but also in midmarket and larger companies across the industry vertical. As the number of approved CGT products continues to rise, investors are increasingly interested in sectors such as raw materials, manufacturing equipment and services, and logistics. With the potential for substantial growth ahead, understanding the complexities and opportunities of the CGT market will be essential for investors seeking to capitalize on this development.
AVP (Patent Intelligence and Analytics Services)
2moThanks for sharing Anshul Mangal